Home > Boards > US Listed > Biotechs >

Resverlogix Corp. (RVXCF)

Add RVXCF Price Alert      Hide Sticky   Hide Intro
Moderator: noretreat
Search This Board: 
Last Post: 4/17/2018 5:57:58 PM - Followers: 23 - Board type: Free - Posts Today: 0

Resverlogix Corp., a biotechnology company, engages in the development of novel therapies for cardiovascular disease (CVD), cancer, and fibrotic diseases. The company's development programs include NexVas Plaque Regression, a technology platform, which is in two Phase 2b clinical trials with RVX-208 for the development of drugs that increase ApoA-I to reduce the risk of CVD; and IL-6 and IL-17, which are cytokine mediators for the treatment of autoimmune diseases, as well as technology for the development of drugs in the areas of multiple sclerosis and rheumatoid arthritis. Its development programs also include NexVas Alzheimer's Disease that focuses on the effects of ApoA-I production on cognition; memory; and both plasma and cerebrospinal fluid biomarkers, such as Amyloid Beta 40, 42, tau, and P-tau; and ReVas, a research stage technology for the development of therapeutics to be used with medical devices for the treatment of cardiovascular diseases. The company is headquartered in Calgary, Canada.

Atherosclerosis is the key underlying cause of cardiovascular disease (CVD) which is responsible for more than 18 million deaths per year worldwide. Atherosclerosis burden results from the accumulation of fat and cholesterol in the artery wall, leading to plaque that causes narrowing and hardening of the arteries, resulting in a loss of elasticity and function. The projected direct and indirect medical costs of CVD in the U.S. will grow from $500 billion in 2012 to $1.2 trillion by 2030 and the largest percentage of this cost is associated with the treatment of atherosclerosis.
The image below illustrates the progression of atherosclerosis in CVD patients. As the disease progresses, the patient develops more severe coronary artery disease (CAD) resulting in increased risk of morbidity and death.



Please mouse over the interactive image to learn about the ApoA-I/HDL Particle.

The most abundant protein in HDL is ApoA-I and it serves as the building block for high-density lipoprotein (HDL or the "good cholesterol") particles. Increased production of ApoA-I protein will result in the synthesis of new HDL particles. These newly synthesized HDL particles are more' functional' because of their ample capacity to remove cholesterol from atherosclerotic plaques. The efflux of cholesterol from the plaque to HDL is called reverse cholesterol transport (RCT). The goal of enhanced RCT with newly synthesized HDL is to remove cholesterol from plaque in the arteries, subsequently regressing atherosclerosis. ApoA-I production therapeutics are the only technologies to date to efficiently remove and regress atherosclerotic plaque in high risk CVD patients.


Reverse cholesterol transport (RCT) is the natural process within the body that describes how HDL removes cholesterol from atherosclerotic plaques found in the wall of arteries. Cholesterol removed from the plaque is transported on the HDL particle to the liver for excretion from the body in the bile. Newly synthesized HDL particles are flat and empty and thus have the most function in mediating RCT.

RVX-208 & MOA


RVX-208 is a first-in-class, small molecule that inhibits BET bromodomains. It is currently being evaluated in a phase 2b clinical trial for its ability to reverse and/or stabilize atherosclerotic disease. RVX-208 acts to increase the production of ApoA-I protein which in turn is used to make new high-density lipoprotein (HDL) particles. These functional HDL particles are flat and empty and can efficiently remove plaque via reverse cholesterol transport (RCT), the natural process through which atherosclerotic plaque is transported out of the arteries and removed from the body by the liver.


RVX-208 acts via an epigenetic mechanism leading to enhanced activity of the ApoA-I gene resulting in increased production of the protein. RVX-208 works by binding to a target called a BET protein. Within the BET protein there are two specialized regions known as bromodomains. Each bromodomain can recognize and bind to an acetylated lysine. This modified amino acid is found in histones bound to DNA. When a BET protein, through the actions of a bromodomain, finds an acetylated lysine and binds to it, this epigenetic process is called 'reading'. When RVX-208 binds to the BET protein, it triggers a cascade of events leading to increased ApoA-I gene transcription and eventually production of the protein. RVX-208 is the first in this class of compounds to enter into clinical development. Clinical experience with RVX-208 demonstrates that BET inhibitors can be both safe and efficacious when given chronically.


RVX-208 has successfully completed a Phase 2b clinical trial 'SUSTAIN' and a second Phase 2b trial 'ASSURE' is ongoing.


In this Phase 2b clinical trial of 176 patients with established atherosclerotic CVD, RVX-208 significantly increased HDL-C, the primary endpoint. SUSTAIN also successfully met secondary endpoints, showed increases in levels of Apo-AI and large HDL particles, both believed to be important factors in enhancing reverse cholesterol transport activity. The SUSTAIN trial also showed that RVX-208 was safe when given daily for 6 months and increases in alanine aminotransferase (ALT) reported in previous trials were infrequent and transient with no new increases observed beyond week 12 of the 24-week trial.


ASSURE is a Phase 2b clinical trial that will evaluate the ability of RVX-208, to regress atherosclerotic disease versus placebo using intravascular ultrasound (IVUS) technology in patients with high-risk CVD. ASSURE is a 26-week, multi-center, double-blind, randomized, parallel group, placebo-controlled clinical trial. The primary trial endpoint will be the change in percent atheroma volume from baseline to 26 weeks measured by IVUS. Secondary objectives for ASSURE are evaluating the safety and tolerability of RVX-208 and effects of RVX-208 on HDL and non-HDL lipid parameters. IVUS technology will also be used to evaluate the changes in plaque stability, an important factor affecting risk of myocardial infarction. Over 310 patients have been enrolled of which 25% will receive placebo and 75% given 100 mg of RVX-208 twice daily.

ASSURE enrollment was completed September 2012. Data is expected in the first half of 2013.

All clinical trials are led by the Cleveland Clinic.


Following the phase 2b program, phase 3 clinical outcomes trials are planned. They will encompass high risk patients with coronary artery disease and with low baseline HDL. In addition, these patients will have at least one more risk factor such as diabetes, smoking or high blood pressure. These trials are often designed with a certain number of events to be observed such as cardiovascular death, non-fatal myocardial infarction, stroke or re-vascularization.

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RVXCF News: Resverlogix Officially Attains Phase 3 Status With a European Regulatory Authority 06/22/2015 07:30:00 AM
RVXCF News: Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangemen... 04/27/2015 07:00:00 AM
RVXCF News: Week In Review: aTyr Pharma To Raise $86 Million In IPO 04/12/2015 06:07:02 AM
RVXCF News: Resverlogix Receives Two Patents for RVX-208 in China 04/07/2015 07:30:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#476   450,000 shares traded today out of 175,000,000.under 3/10ths noretreat 04/17/18 05:57:58 PM
#475   Offering was announced with no prices or details. noretreat 04/17/18 04:41:29 PM
#474   Any ideas what happened to the price today? big orange 04/17/18 04:20:50 PM
#473   Good to have the funding nailed down but noretreat 04/14/18 05:07:32 PM
#472   New report from ZAck's noretreat 04/14/18 05:05:04 PM
#471   Resverlogix Announces Sixth Positive Recommendation From Data Safety noretreat 02/26/18 07:58:37 AM
#470   Thanks big orange 02/07/18 03:25:51 PM
#469   A big Phase 3 with a partial analysis noretreat 02/07/18 02:25:47 PM
#468   Is RVXCF in a phase2 or phase3 study? big orange 02/07/18 12:48:41 PM
#467   zzzzzzzzzzzzzzzz...where is that ole' FA? noretreat 01/25/18 04:20:49 PM
#466   Strong. "Current therapies fail to counter progressive noretreat 01/09/18 05:47:45 PM
#465   Another Journal article on apabetalone noretreat 01/09/18 05:41:29 PM
#464   Resverlogix and Medison Pharma Ltd. Announce Strategic Licensing noretreat 01/08/18 09:05:27 AM
#463   After 188 MACE are observed. If Apabetalone noretreat 01/02/18 12:32:47 PM
#462   Does anyone have any idea when the interim big orange 12/30/17 12:20:49 PM
#461   RVXCF is officially on the watch list....coverage initiated. Matagordaville 12/12/17 03:22:19 PM
#460   Nature’s Recent Scientific Reports Publication Describes How Apabetalone noretreat 12/12/17 09:31:09 AM
#459   New blog posting, warrants vs shares ledrog_krill 12/11/17 10:14:31 PM
#458   We have seen this before.... ledrog_krill 12/11/17 12:02:06 PM
#457   approaching a 90% gain. this is just noretreat 12/11/17 10:18:41 AM
#456   The hardest part of this $0 sum game.... ledrog_krill 12/08/17 09:02:16 PM
#455   now up 70+%...Merry Christmas! noretreat 12/08/17 04:00:17 PM
#454   shhhhhh noretreat 12/07/17 03:10:29 PM
#453   You called me a friend....ahhhhhhhhhhhhhhhh ledrog_krill 12/07/17 11:45:16 AM
#452   From a friend on another board: noretreat 12/07/17 10:46:30 AM
#451   Resverlogix Repays $68.8 Million Loan noretreat 12/07/17 10:40:32 AM
#450   Live stream video analysis on youtube ledrog_krill 12/06/17 07:18:50 PM
#449   Blog post, China has been hot of late... ledrog_krill 12/04/17 01:10:23 PM
#448   here we go.. noretreat 12/04/17 09:30:25 AM
#447   30% gain so far. Lots more room noretreat 11/24/17 04:38:43 PM
#446   Seeking Alpha ledrog_krill 11/24/17 10:29:25 AM
#445   Can you post the link here? ledrog_krill 11/19/17 06:23:37 PM
#444   The link to the report worked fine... noretreat 11/19/17 08:56:34 AM
#443   Great find.... ledrog_krill 11/18/17 04:26:20 PM
#442   so buy now or weep later... noretreat 11/18/17 11:47:03 AM
#441   Excerpt from an unpaid analysis: "We believe noretreat 11/18/17 11:46:45 AM
#440   Nice. (the link may not work) noretreat 11/18/17 11:08:20 AM
#439   New blog post at Avoid The Bag.... ledrog_krill 11/05/17 02:40:25 AM
#438   Read the last PR about the DSMB + reccomendation.... ledrog_krill 11/03/17 05:42:00 PM
#437   Does anyone know what the actual number of big orange 11/02/17 11:00:43 AM
#436   Are referring to the Futility Analysis... ledrog_krill 10/31/17 07:35:09 PM
#435   anyone have any ideas when the interim data big orange 10/31/17 12:21:00 PM
#434   $8,000,000 on the balance sheet. Wasn’t there yesterday. noretreat 10/25/17 08:26:47 AM
#433   Is this good or bad? The last big orange 10/24/17 04:02:57 PM
#432   Oct 24 (Reuters) - Resverlogix Corp(RVXCF) noretreat 10/24/17 08:28:41 AM
#431   Resverlogix Announces Right of First Refusal Agreement With noretreat 10/24/17 07:53:51 AM
#430   I'm ready for anything next week..... ledrog_krill 10/14/17 11:53:59 PM
#429   A good summary of why I am invested. noretreat 10/14/17 02:41:07 PM
#428   I picked up another 1K warrants.... ledrog_krill 10/13/17 11:52:18 PM
#427   Today's announcement solves the giant problem. It noretreat 10/13/17 01:50:27 PM